Literature DB >> 7820299

Nuclear DNA analysis and prognosis in carcinoma of the thyroid gland. A nationwide study in Iceland on carcinomas diagnosed 1955-1990.

J G Jónasson1, J Hrafnkelsson.   

Abstract

The purpose of this study was to ascertain whether DNA ploidy status and S-phase fraction affected the prognosis of patients with carcinoma of the thyroid gland. We reviewed all malignant thyroid tumours diagnosed in Iceland from 1955 to 1990. In all, 494 thyroid carcinomas were diagnosed during that period. By analysing tumour material from paraffin blocks by flow cytometry we were able to evaluate the ploidy status in 424 tumours and the S-phase value in 417 tumours. We detected aneuploid cell populations in 9.7% of papillary carcinomas, 24.3% of follicular carcinomas, 42.9% of medullary carcinomas and 78.6% of anaplastic carcinomas. Some 57% of tumours, mainly papillary carcinomas, had an S-phase value of less then 3%, whereas most of the other histological types of carcinoma, including all the anaplastic tumours, had an S-phase value of > or = 3%. Univariate analysis indicated that both ploidy status and S-phase fraction were significant variables. When taking into account known prognostic variables of thyroid carcinoma in a multivariate analysis, however, neither ploidy status nor S-phase value proved significant. We conclude that DNA ploidy status and S-phase values are not independent prognostic factors in thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7820299     DOI: 10.1007/bf00189572

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  43 in total

1.  Nuclear DNA content and behavior of oxyphil thyroid tumors.

Authors:  L Bondeson; E Azavedo; A G Bondeson; T Caspersson; O Ljungberg
Journal:  Cancer       Date:  1986-08-01       Impact factor: 6.860

2.  Histopathologic characteristics and nuclear DNA content as prognostic factors in medullary thyroid carcinoma. A nationwide study in Sweden. The Swedish MTC Study Group.

Authors:  U Bergholm; H O Adami; G Auer; R Bergström; M Bäckdahl; L Grimelius; G Hansson; O Ljungberg; E Wilander
Journal:  Cancer       Date:  1989-07-01       Impact factor: 6.860

3.  DNA aneuploidy in anaplastic carcinoma of the thyroid gland.

Authors:  P J Klemi; H Joensuu; E Eerola
Journal:  Am J Clin Pathol       Date:  1988-02       Impact factor: 2.493

4.  Measurement of nuclear DNA content in thyroid diagnosis.

Authors:  A Bengtsson; J Malmaeus; L Grimelius; H Johansson; J Pontén; J Rastad; G Akerström
Journal:  World J Surg       Date:  1984-08       Impact factor: 3.352

5.  Prognostic value of nuclear DNA content in papillary thyroid carcinoma.

Authors:  K Cohn; M Bäckdahl; G Forsslund; G Auer; G Lundell; T Löwhagen; E Tallroth; J S Willems; A Zetterberg; P O Granberg
Journal:  World J Surg       Date:  1984-08       Impact factor: 3.352

6.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.

Authors:  D W Hedley; M L Friedlander; I W Taylor; C A Rugg; E A Musgrove
Journal:  J Histochem Cytochem       Date:  1983-11       Impact factor: 2.479

7.  Indicators of prognosis in node-negative breast cancer.

Authors:  H Sigurdsson; B Baldetorp; A Borg; M Dalberg; M Fernö; D Killander; H Olsson
Journal:  N Engl J Med       Date:  1990-04-12       Impact factor: 91.245

8.  The diagnostic value of flow cytometric DNA measurements in selected disorders of the human thyroid.

Authors:  J V Johannessen; M Sobrinho-Simões; T Lindmo; K O Tangen
Journal:  Am J Clin Pathol       Date:  1982-01       Impact factor: 2.493

9.  Prognostic value of nuclear DNA content in follicular thyroid tumours.

Authors:  M Bäckdahl; G Auer; G Forsslund; P O Granberg; B Hamberger; G Lundell; T Löwhagen; A Zetterberg
Journal:  Acta Chir Scand       Date:  1986-01

10.  A flow cytometric deoxyribonucleic acid analysis of papillary thyroid carcinoma.

Authors:  J V Johannessen; M Sobrinho-Simões; K O Tangen; T Lindmo
Journal:  Lab Invest       Date:  1981-10       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.